肝硬化患者红细胞补体受体Ⅰ型分子密度相关基因多态性与其数量变化的研究

Study on the genomic density polymorphism and the quantity of CR I expressed on erythrocyte in the patients with hepa- tocirrhosis

研究乙肝后肝硬化代偿和失代偿患者红细胞CR1分子数量及其与CR1密度相关基因多态性的关系,探讨肝炎后肝硬化红细胞膜分子的变化在肝硬化疾病发展中的意义。采用酶免疫分析间接法检测乙肝后肝硬化患者红细胞CR1分子数量;用PCR、Hind Ⅲ酶切和凝胶电泳法检测红细胞CR1密度相关基因多态性。乙肝后肝硬化患者的红细胞CR1分子数量下降(P<0.01),失代偿者尤为显著(P<0.01)。乙肝后肝硬化患者红细胞CR1分子数量下降与肝硬化发生、发展有关。红细胞CR1分子数量表达下降主要与后天性因素有关。对乙肝后肝硬化患者进行红细胞CR1分子测定或动态观察,对探讨肝炎后肝硬化的发病机理、预后和转归具有重要意义。

In order to understand the clinic implication of these changes on the development of hepatitis B related cirrhosis, the relationship between the quantity and the genomic density polymorphism of complement receptor type I ( CR I ) expressed on ery-throcyte in the patients with hepatitis B related cirrhosis was studied. The quantity of CR I expressed on erythrocyte were measured by the quantitative assay. The genomic density polymorphism of CR I (HH type, HL type, LL type)were determined by polymerase chain reaction (PCR), Hind Ⅲ restriction enzyme digestion and gel electrophoresis. The expression of CR I on erythrocyte in the patients with hepatitis B related cirrhosis was significantly lower than that in the normal individuals ( P < 0.01). Especially, in the patients with decompensated cirrhosis, its expression was the lowest ( P < 0.01) . The reduced expression of CR I on erythrocyte was likely related to the onset and the development of hepatocirrhosis. Defective expression of CR I in the patients is mostly acquired after birth. Detecting the expression levels of CR I on erythrocyte and the genomic density polymorphism of CR I will significantly contribute to the exploration of the mechanism involved in development of hepatocirrhosis, the observation of therapeutic efficacy and prognosis judgments.